Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a simple blood or urine test replace prostate biopsies?

NCT ID NCT06144619

First seen Nov 16, 2025 · Last updated Jun 22, 2026 · Updated 29 times

Summary

This study looks at whether non-invasive tests—like blood, urine, and genetic analysis—can help track prostate cancer progression without repeated biopsies. Researchers will follow 500 men with low, intermediate, or high-risk prostate cancer as they receive standard care. The goal is to find biomarkers that signal when the disease is getting worse, potentially reducing the need for invasive procedures.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better ways to monitor prostate cancer without repeated invasive biopsies, improving patient comfort and care decisions.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly improve health. It is currently suspended, and results may not change practice for years.

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.